Form 4 for GNLX GENELUX Corp
Accepted 2024-07-08 00:00:00 ET · period of report 2024-02-19 · accession 0001415889-24-019344 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-07-08 | 2024-02-19+ | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +15.2K | 9,396 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-14 | A | A | 11,557 | $0.00 | 20,953 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-19 | A | A | 3,661 | $0.00 | 9,396 | D | — | — |